Tvardi Therapeutics (TVRD) Intangibles (2024 - 2026)

Tvardi Therapeutics (TVRD) posted Intangibles of $306000.0 for Q1 2026, down 4.97% sequentially from $322000.0 in Q4 2025.

Tvardi Therapeutics (TVRD) Intangibles (2024 - 2026) Analysis & Trends

Tvardi Therapeutics has reported Intangibles for 3 years, with the latest figure at $306000.0 in Q1 2026.

Quarterly Intangibles changed N/A year-over-year to $306000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $306000.0 (changed N/A YoY) and the FY2025 annual result came in at $322000.0, down 16.36% from the prior year.
Intangibles eased to $306000.0 in Q1 2026 per TVRD's latest filing, from $322000.0 in the prior quarter.
Over five years, Intangibles peaked at $385000.0 in Q4 2024 and troughed at $306000.0 in Q1 2026.
A 3-year average of $341000.0 and a median of $338000.0 in 2025 frame the typical range for Intangibles.
The widest YoY moves for Intangibles: up 16.36% in 2025, down 16.36% in 2025.
Over 3 years, Intangibles stood at $385000.0 in 2024, then fell by 16.36% to $322000.0 in 2025, then fell by 4.97% to $306000.0 in 2026.
According to Business Quant data, Intangibles over the past three periods registered $306000.0, $322000.0, and $338000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Intangibles (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn	412.80 Mn
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn	1.31 Bn
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn	266.00 Mn
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn	-
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn	60.96 Mn
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn	-
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn	-
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn	93.49 Mn
9	Royalty Pharma	27.27 Bn	26.43 Bn	-	-
10	Tvardi Therapeutics	17.36 Mn	17.36 Mn	-	291,000.00

Download Data